Chronic NaHS treatment decreases oxidative stress and improves endothelial function in diabetic mice

Diab Vasc Dis Res. 2017 May;14(3):246-253. doi: 10.1177/1479164117692766. Epub 2017 Feb 1.

Abstract

Hydrogen sulphide (H2S) is endogenously produced in vascular tissue and has anti-oxidant and vasoprotective properties. This study investigates whether chronic treatment using the fast H2S donor NaHS could elicit a vasoprotective effect in diabetes. Diabetes was induced in male C57BL6/J mice with streptozotocin (60 mg/kg daily, ip for 2 weeks) and confirmed by elevated blood glucose and glycated haemoglobin levels. Diabetic mice were then treated with NaHS (100 µmol/kg/day) for 4 weeks, and aortae collected for functional and biochemical analyses. In the diabetic group, both endothelium-dependent vasorelaxation and basal nitric oxide (NO) bioactivity were significantly reduced ( p < 0.05), and maximal vasorelaxation to the NO donor sodium nitroprusside was impaired ( p < 0.05) in aorta compared to control mice. Vascular superoxide generation via nicotine adenine dinucleotide phosphate (NADPH) oxidase ( p < 0.05) was elevated in aorta from diabetic mice which was associated with increased expression of NOX2 ( p < 0.05). NaHS treatment of diabetic mice restored endothelial function and exogenous NO efficacy back to control levels. NaHS treatment also reduced the diabetes-induced increase in NADPH oxidase activity, but did not affect NOX2 protein expression. These data show that chronic NaHS treatment reverses diabetes-induced vascular dysfunction by restoring NO efficacy and reducing superoxide production in the mouse aorta.

Keywords: Hydrogen sulphide; NADPH oxidase; diabetes; endothelial dysfunction; oxidative stress; vasoprotection.

MeSH terms

  • Animals
  • Antioxidants / administration & dosage*
  • Blood Glucose / metabolism
  • Diabetes Mellitus, Experimental / blood
  • Diabetes Mellitus, Experimental / complications
  • Diabetes Mellitus, Experimental / drug therapy*
  • Diabetic Angiopathies / etiology
  • Diabetic Angiopathies / metabolism
  • Diabetic Angiopathies / physiopathology
  • Diabetic Angiopathies / prevention & control*
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Endothelium, Vascular / drug effects*
  • Endothelium, Vascular / metabolism
  • Endothelium, Vascular / physiopathology
  • Glycated Hemoglobin / metabolism
  • Male
  • Mice, Inbred C57BL
  • Muscle, Smooth, Vascular / drug effects
  • Muscle, Smooth, Vascular / metabolism
  • Muscle, Smooth, Vascular / physiopathology
  • NADPH Oxidase 2 / metabolism
  • Nitric Oxide / metabolism
  • Nitric Oxide Donors / pharmacology
  • Nitric Oxide Synthase Type III / metabolism
  • Oxidative Stress / drug effects*
  • Sulfides / administration & dosage*
  • Superoxides / metabolism
  • Time Factors
  • Vasodilation / drug effects
  • Vasodilator Agents / pharmacology

Substances

  • Antioxidants
  • Blood Glucose
  • Glycated Hemoglobin A
  • HbA(1c) protein, mouse
  • Nitric Oxide Donors
  • Sulfides
  • Vasodilator Agents
  • Superoxides
  • Nitric Oxide
  • Nitric Oxide Synthase Type III
  • Nos3 protein, mouse
  • Cybb protein, mouse
  • NADPH Oxidase 2
  • sodium bisulfide